|
|
LTK72 vaccine adjuvant |
|
Vaxjo ID |
103 |
|
Vaccine Adjuvant Name |
LTK72 vaccine adjuvant |
|
Alternative Names |
LTR72 |
|
Adjuvant VO ID |
VO_0001344
|
|
Description |
LTR72, is a mutant form of heat-labile Escherichia coli enterotoxin (LT) that contains a substitution Ala → Arg in position 72 of the A subunit, showed only 0.6% of the LT enzymatic activity, was 100,000-fold less toxic than wild-type LT in Y1 cells in vitro, and was at least 20 times less effective than wild-type LT in the rabbit ileal loop assay in vivo. At a dose of 1 μg, LTR72 exhibited a mucosal adjuvanticity, similar to that observed with wild-type LT, better than that induced by the nontoxic, enzymatically inactive LTK63 mutant, and much greater than that of the recombinant B subunit (Giuliani et al., 1998). |
|
Stage of Development |
Clinical Trial |
| Related Vaccine(s) |
|
| References |
Giuliani et al., 1998: Giuliani MM, Del Giudice G, Giannelli V, Dougan G, Douce G, Rappuoli R, Pizza M. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. The Journal of experimental medicine. 1998; 187(7); 1123-1132. [PubMed: 9529328].
|
|
